MediciNova (NASDAQ: MNOV) is one of 297 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare MediciNova to similar businesses based on the strength of its earnings, profitability, valuation, analyst recommendations, institutional ownership, risk and dividends.
Valuation and Earnings
This table compares MediciNova and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MediciNova Competitors||$269.81 million||-$28.62 million||-31.64|
This table compares MediciNova and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
18.8% of MediciNova shares are owned by institutional investors. Comparatively, 52.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 15.2% of MediciNova shares are owned by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility & Risk
MediciNova has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, MediciNova’s rivals have a beta of 1.53, meaning that their average share price is 53% more volatile than the S&P 500.
This is a summary of recent ratings for MediciNova and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.52%. Given MediciNova’s rivals higher possible upside, analysts clearly believe MediciNova has less favorable growth aspects than its rivals.
MediciNova rivals beat MediciNova on 7 of the 13 factors compared.
Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.